No Data
No Data
Qianjiang Yongan Pharmaceutical (002365.SZ): A total of 1.17% of shares have been repurchased.
On December 2, 2023, Gelonghui reported that qianjiang yongan pharmaceutical (002365.SZ) announced that as of the end of November 2024, the company has cumulatively repurchased 3,442,350 shares of the company through centralized bidding, accounting for 1.17% of the total share capital. The highest fill price was 7.30 yuan/share, the lowest fill price was 6.67 yuan/share, and the total amount of the trade was 24,170,198.50 yuan (excluding transaction fees). The implementation of the company's share repurchase complies with relevant laws and regulations and aligns with the company's established repurchase plan.
Express News | Qianjiang Yongan Pharmaceutical: Obtained an invention patent for the recovery of impurities from taurine mother liquor.
Yongan Pharmaceutical: Report for the third quarter of 2024
Qianjiang YongAn Pharmaceutical (002365.SZ) released its performance for the first three quarters, with a net income of 61.8552 million yuan, a year-on-year increase of 33.23%.
Qianjiang Yongan Pharmaceutical (002365.SZ) released the third quarter report for 2024, achieving revenue in the first three quarters...
Qianjiang Yongan Pharmaceutical (002365.SZ): A controlling subsidiary has received a utility model patent certificate.
On September 18, Gelonghui announced that Yongan Pharmaceutical (002365.SZ) recently announced that its holding subsidiary, Hubei Ling'an Technology Co., Ltd. (referred to as 'Ling'an Technology') received a utility model patent certificate issued by the State Intellectual Property Office. The utility model is named as a feeding mechanism for processing water reducing agents. Ling'an Technology, a holding subsidiary of the company, has been committed to the research and development and application of polycarboxylic acid water reducers and all ether technologies. The acquisition of this utility model patent is beneficial for Ling'an Technology to fully leverage its advantages in independent intellectual property rights, continuously innovate technology, and promote Ling'an Technology's leading position in the field of ethers and polycarboxylic acid water reducers.
Express News | Qianjiang Yongan Pharmaceutical: Obtained an invention patent certificate.
No Data
No Data